Key Points
- Capricor CFO Anthony Bergmann sold 25,000 shares on May 1 at an average price of $31.70 for $792,500 under a pre‑arranged Rule 10b5‑1 plan; following the transaction he directly owns 8,223 shares, a 75.25% reduction. He also sold 25,000 shares on March 31 at $30.13 for about $753,250.
- Stock and analyst context: CAPR trades well above its 52‑week low ($4.30) with a 52‑week high of $40.37 and a $1.94 billion market cap, and the consensus among analysts is a "Moderate Buy" (9 Buys, 1 Sell) with an average price target of $46.09.
Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Anthony Bergmann also recently made the following trade(s):
- On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.13, for a total value of $753,250.00.
Capricor Therapeutics Stock Performance
Shares of CAPR stock opened at $33.50 on Tuesday. Capricor Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -14.82 and a beta of 0.48. The stock's 50-day simple moving average is $31.11 and its 200-day simple moving average is $22.76.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities analysts forecast that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have recently commented on CAPR. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the stock an "overweight" rating in a research note on Friday, March 13th. B. Riley Financial upped their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a "buy" rating in a research report on Friday, March 13th. Piper Sandler restated an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Finally, Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, January 11th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.09.
Get Our Latest Stock Report on CAPR
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Patriot Financial Group Insurance Agency LLC purchased a new stake in Capricor Therapeutics in the first quarter valued at $304,000. Pictet Asset Management Holding SA acquired a new position in shares of Capricor Therapeutics in the 1st quarter valued at about $250,000. Focused Wealth Management Inc acquired a new position in shares of Capricor Therapeutics in the 1st quarter valued at about $203,000. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics in the first quarter worth about $193,000. Finally, Creek Drive Management Group LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth about $1,039,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
